Table 1 Baseline characteristics of patients
From: Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
Global population N=79 | EMR N=19 | Relapse without EM disease N=25 | P-value | |
|---|---|---|---|---|
Sex | ||||
Male | 30 (38%) | 9 (47%) | 9 (36%) | 0.4474 |
ISS at diagnosis | ||||
MD | 22 | 4 | 8 | |
1 | 23 (40%) | 5 (33%) | 8 (47%) | 0.7432 |
2 | 17 (30%) | 5 (33%) | 4 (23%) | |
3 | 17 (30%) | 5 (33%) | 5 (29%) | |
Plasma cell leukemia | 7 (9%) | 3 (16%) | 3 (12%) | 1.0000 |
Age at allo-SCT median (min–max) | 55 (35–68) | 54 (35–66) | 58 (43–66) | 0.0640 |
Delay between diagnosis and allo-SCT (years) median (min–max) | 3.1 (0.5–17) | 3.2 (0.76–17.0) | 3.9 (0.9–11.3) | 0.7046 |
Number of lines before allo-SCT | ||||
1 | 10 (13%) | 3 (16%) | 1 (4%) | 0.4868 (0–1v2–6) |
2 | 37 (47%) | 11 (58%) | 12 (48%) | |
3 | 17 (22%) | 3 (16%) | 7 (28%) | |
4 | 13 (16%) | 2 (11%) | 3 (12%) | |
6 | 2 (2%) | 0 (0%) | 2 (8%) | |
Bortezomib before allo-SCT | 59 (75%) | 12 (63%) | 19 (76%) | 0.3551 |
Thalidomide before allo-SCT | 29 (37%) | 8 (42%) | 11 (44%) | 0.9000 |
Lenalidomide before allo-SCT | 32 (41%) | 3 (16%) | 14 (56%) | 0.0067 |
Number of auto-SCT before allo-SCT | ||||
0 | 2 (3%) | 0 (0%) | 0 (0%) | 0.0899 |
1 | 36 (46%) | 5 (26%) | 14 (56%) | |
2 | 39 (49%) | 13 (68%) | 10 (40%) | |
3 | 2 (3%) | 1 (5%) | 1 (4%) | |
Tandem Auto-allo-SCT | 12 (15%) | 2 (10%) | 4 (16%) | |
Early allo-SCT (2000–2005) | 15 (34%) | 9 (47%) | 6 (24%) | 0.1053 |
Disease status at allo-SCT | ||||
Progression | 7 (9%) | 1 (5%) | 3 (12%) | 0.4170 |
Stable disease | 5 (6%) | 1 (5%) | 3 (12%) | |
Partial response | 21 (27%) | 7 (37%) | 5 (20%) | |
Very good partial response | 26 (33%) | 3 (16%) | 9 (36%) | |
Near complete response | 4 (5%) | 1 (5%) | 1 (4%) | |
Complete response | 16 (20%) | 6 (32%) | 4 (16%) | |
